Section Arrow
COCP.NASDAQ
- Cocrystal Pharma
Quotes are at least 15-min delayed:2026/04/17 23:29 EDT
Regular Hours
Last
 1.51
-0.06 (-3.82%)
Day High 
1.58 
Prev. Close
1.57 
1-M High
2.0299 
Volume 
383.87K 
Bid
1.49
Ask
1.51
Day Low
1.49 
Open
1.545 
1-M Low
Market Cap 
21.64M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.46 
20-SMA 1.25 
50-SMA 1.11 
52-W High 2.67 
52-W Low 0.8588 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.78/-0.64
Enterprise Value
22.81M
Balance Sheet
Book Value Per Share
0.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.2572+0.0049+1.94%0.09PE
PBMPsyence Biomedical Ltd.7.6+1.73+29.47%-- 
GERNGeron Corp1.68-0.01-0.59%-- 
IBRXImmunityBio7.7+0.45+6.21%-- 
ADMAADMA Biologics11.01+0.27+2.51%17.92PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.